Transimmune thrombocytopenia

Transimmune thrombocytopenia (transimmune antithromboplastic condition, thrombocypatia), also known as congenital Duplay thrombocypathia, is a group of hereditary disorders of hemostasis, the main manifestation of which is isolated thrombocytopenic purpura; the disease develops in homozygotes immediately after birth, while the level of immune anticoagulant activity of antithrombin III and protein C in the blood serum remains normal or low.

In simple terms, this is a congenital bleeding disorder. The disease is inherited from one of the parents. The functioning of the immune system is disrupted.

Thrombotic platelets are a rare condition in which a person produces few platelets. This occurs as a result of a disorder in the immune system, which can react to certain antigens and lead to the formation of antibodies against its own cells.

The main cause of transimmune thrombocytopenia is an autoimmune process in which the immune system mistakenly attacks the body's own cells. This process can be caused by various factors, including genetics, viral infections, medications and other factors.

Clinical manifestations of thrombocytopenic transimmunism can vary greatly depending on the stage of development of the disease and the individual characteristics of the patient’s body. In the early stages, symptoms may be absent or mild. However, as the disease progresses, patients may experience more severe symptoms.

One of the most common symptoms is bleeding, which can appear as small amounts of blood in the urine, stool, discharge from the nose or mouth, bruising of the skin, and other areas. Bleeding most often occurs after minor trauma or surgery. In addition, patients with this form of thrombocytopenia may have severe periods that are accompanied by heavy discharge.

To diagnose transmmune thrombocytopeia, it is necessary to conduct a blood test to determine the number of platelets and study the antibodies formed against one’s own platelets. A bone marrow biopsy may also be used to look for specific changes in platelet structure.

Treatment for transmunal platelet ompin depends on the cause of the disease. In some cases, immunosuppressive therapy may be required, which reduces the activity of the immune system. Drugs that increase platelet levels in the blood, such as prednisolone, may also be used.